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Introduction {#sec005}
============

Anti-coagulant drugs (warfarin, apixaban, edoxaban dabigatran and rivaroxaban) are used in the treatment of atrial fibrillation (AF). Anti-coagulants prevent thromboses which cause cardiovascular event or strokes in AF patients; however, excessive anticoagulation results in bleeding. Package inserts report major bleeding events in approximately 2% in patients treated with warfarin or Direct Oral Anti-Coagulant (DOAC).

In a sub-analysis of warfarin and rivaroxaban in a phase 3 clinical trial, the proportion of bleeding were higher in the group with 7--9 and over 10 co-administered drugs, than in that at with less than 5 drugs for the first-dose of anti-coagulation \[[@pone.0238233.ref001]\]. Consistent results were reported in a warfarin vs. apixaban phase 3 study of polypharmacy for the risk for bleeding \[[@pone.0238233.ref002]\]. This suggests that polypharmacy in AF patients treated with anti-coagulants is likely to increase bleeding events.

In Japan, there were approximately 0.7 million AF patients (0.56% of Japanese population) in 2005 and the prevalence is increasing with the increase in life expectancy \[[@pone.0238233.ref003]\]. The increasing numbers of AF patients is now considered a major global health care problem. A large-scale cohort study from England showed that the socioeconomic status affected the mortality of ischemic stroke or intracerebral hemorrhage adjusted AF \[[@pone.0238233.ref004]\]. It is important to identify the predictive factors for anti-coagulant-related bleeding in the working-age population, so as to facilitate prediction of social burdens.

We previously reported that anti-coagulants are involved in drug-drug interactions that increase the incidence of bleeding events after starting anticoagulants \[[@pone.0238233.ref005]\]. Briefly, pharmacokinetic and pharmacodynamic drug-drug interactions were associated with bleeding events in 3290 AF patients according to a large claims database with 3-month observation periods. Nevertheless, the study did not determine the risk factors for bleeding because of the short observation period. Therefore, in the present study, we aimed to: 1) measure polypharmacy in AF patients treated with anti-coagulants, and 2) identify predictive factors associated with bleeding after starting anti-coagulant treatment using a large claims data with 12-month observation period from Japan.

Methods {#sec006}
=======

Data source {#sec007}
-----------

The large health insurance claims database was developed by JMDC Co. Ltd., Tokyo, Japan \[[@pone.0238233.ref006]\]. JMDC collects medical and pharmacy claims from more than 50 occupation-based public health insurance agencies for corporate employees and their family members. As of August 2016, the database included 3600000 recipients aged 0--74 years, representing 2.0% of the Japanese population.

Case identification and pattern analysis for the number of co-administered drugs {#sec008}
--------------------------------------------------------------------------------

Cases were obtained from 8926 AF patients treated with anti-coagulant drugs (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) between 2004 and 2016 \[[@pone.0238233.ref006]\]. Exclusion criteria included lack of data regarding the prescription date, 4-month screening period, and 12-month observation period. A total of 2796 patients were analyzed for the frequency of polypharmacy at the first-dose of anti-coagulant administration, and the predictive factors for bleeding events after starting anticoagulants, using the first dose of anticoagulants. Concomitant use of warfarin or DOACs was counted as one drug. Polypharmacy was defined as the use of over six drugs for the first-dose of anti-coagulant administration in each patient. Injectable and topical agents were omitted from the counts.

Identification of cases of bleeding and predictive factors associated with bleeding {#sec009}
-----------------------------------------------------------------------------------

Bleeding was identified using the target word "bleeding" or "hemorrhage" in the "Japanese standard disease master" within 12 months after starting anti-coagulants \[[@pone.0238233.ref005]\]; this code was linked to the ICD-10 code. The standard disease master was developed by "The Committee for Controlled Medical Terminology of Japan Association of Medical Sciences" that was responsible for standardizing disease names, and another committee dedicated for assigning codes to the unique disease names. This is set up in the Social Insurance Medical Fee Payment Fund in conjunction with the Medica Information System Development Center \[[@pone.0238233.ref007]\]. The Ministry of Health, Labour and Welfare indicated the \"Japanese standard disease master\" as the standard code for information and use in Japan. This master contains approximately 22000 terms and 2000 modifiers.

Statistical analysis {#sec010}
--------------------

Univariate analyses (Students t-test, Mann--Whitney U-test and Chi-squares test) of the groups for "bleeding" and "without bleeding" were performed using the patient demographics of 2796 patients. Multivariate logistic analysis was performed for all co-factors to estimate the risk for bleeding after administration of warfarin or DOAC in 2796 patients. Patients were stratified based on the presence or absence of a history of cerebrovascular diseases (ICD-10 code: I60--69) because of the different base-condition in AF patients. We followed standard methods to estimate sample sizes for multiple logistic regression; at least ten outcomes were needed for each independent variable. In the model with cerebrovascular disease, bleeding was observed in 77 of 297 patients; to avoid overfitting, we selected a maximum of eight factors.

Associations with potential predictors for bleeding were built using simultaneous methods for gender, age, anti-coagulants including warfarin or DOACs, co-administration of anti-platelets (with or without), the number of co-administered drugs, history of bleeding (with or without) and drug-drug interactions (with or without) that are known to have potent drug-drug interactions with warfarin (azole antifungals, macrolides, amiodarone, and anti-cancer agents), apixaban (azole antifungals and macrolides), dabigatran (azole antifungals, verapamil, amiodarone and macrolides) and rivaroxaban (azole antifungals and macrolides). The reasons for adding these factors were as follows: sex: difference in body size between males and females, anticoagulants: warfarin is associated with a higher risk for bleeding as compared to DOACs \[[@pone.0238233.ref008]\], number of co-administered drugs: co-administration of anti-platelet and drug-drug interactions enhance the bleeding risk for anticoagulants \[[@pone.0238233.ref001], [@pone.0238233.ref002]\], age: the elderly are at a higher risk of bleeding, and past history of bleeding risk: clearly increases bleeding risk. We also added interaction terms for the number of co-administered drugs and patient ages. The reason for adding the interaction terms for the model was that both of these factors were potent factors for bleeding in AF patients; however, the severity of physical conditions were very different between younger and elderly AF patients who received polypharmacy. If an interaction was observed, we stratified the age group as young (age \<60) and elderly (age ≥60 and ≤74 year), because the age of 60 years is the time for drastic changes in the working environment including factors such as retirement, position retirement or altered employment status.

Multi-co-linearity was determined using Spearman's rank correlation for r \>0.6. The model validity was assessed using \"lack of fitness (LOF)\", that the model fit when the value over 0.2. Data were expressed as medians with ranges or means ± standard deviations. Data analysis was performed using JMP 14^®^ (SAS Institute Inc.,-Cary,-NC,-US) and Microsoft Excel add-in software "Excel Stat BellCurve" (SSRI Co. Ltd., Tokyo, Japan). The protocol for this study was approved by the Ethics Committee of Teikyo Heisei University. We did not obtain written or verbal informed consent because of using the anonymous large claims data that fully anonymized before you accessed them. Only limited members working in JMDC inc. had access to the original data \[[@pone.0238233.ref006]\]. Our co-authors could not access the original data.

Results {#sec011}
=======

Polypharmacy in AF patients treated with anti-coagulants {#sec012}
--------------------------------------------------------

A total of 2796 AF patients with (371; male/female: 281/90, 58.6 ± 9.8 y) and without (2425; male/female: 2,093/332, 55.6 ± 9.7 y) bleeding were assessed for prescription patterns of polypharmacy, defined as over six drugs ([Table 1](#pone.0238233.t001){ref-type="table"}). In our dataset, edoxaban was not observed based on our study case identification flow. Polypharmacy was observed in 815 of 2796 (29.1%) patients. In patients with bleeding, prescription patterns for anticoagulants indicated a higher use of warfarin (170/371 vs. 846/2425, p \< 0.0001), but lower use of DOACs. The number of patients with co-administration of antiplatelet agents (p = 0.0010), history of bleeding (p \< 0.0001), and anticoagulant related drug-drug interactions (p = 0.0018) were higher in the bleeding groups ([Table 1](#pone.0238233.t001){ref-type="table"}). The prescription patterns in the study patients, indicated that the median number of co-administered drugs were five (1--18) and four (1--18) in the with and without bleeding groups, respectively ([Table 1](#pone.0238233.t001){ref-type="table"}). The proportions who received polypharmacy with over six drugs were 27.0% (n = 655) and 43.1% (n = 160) in the without and with bleeding groups, respectively (p \< 0.0001) ([Fig 1](#pone.0238233.g001){ref-type="fig"}). The most frequent numbers of co-administered drugs were two (n = 455) and four (n = 61) in the without and with bleeding groups, respectively.

![Frequency of the number of co-administered drugs in 2796 aterial fibrilation patients.](pone.0238233.g001){#pone.0238233.g001}

10.1371/journal.pone.0238233.t001

###### Patients characteristics.

![](pone.0238233.t001){#pone.0238233.t001g}

                                                                                                          With bleeding      Without bleeding   *p*
  ----------------------------------------------------------------------------- ------------------------- ------------------ ------------------ ----------
  n (male/female)                                                               371 (281/90)              2425 (2,093/332)   \<0.0001           
  Age (mean±SD)                                                                 58.6 ± 9.8                55.6 ± 9.7         \<0.0001           
  Number of drugs                                                               5 (1--18)                 4 (1--18)          \<0.0001           
  Anticoagulant agent \[%\]                                                                                                                     
                                                                                Warfarin                  170 \[45.8\]       846 \[34.9\]       \<0.0001
                                                                                Apixaban                  41 \[11.1\]        307 \[12.7\]       0.3821
                                                                                Dabigatran                79 \[21.3\]        647 \[26.7\]       0.0275
                                                                                Rivaroxaban               81 \[21.8\]        625 \[25.8\]       0.1038
  Number of patients co-administered with antiplatelet agent \[%\]              38 \[10.2\]               134 \[5.5\]        0.0010             
  Number of patients with history of bleeding \[%\]                             71 \[19.1\]               40 \[1.6\]         \<0.0001           
  Number of patients with anticoagulants relating drug-drug interaction \[%\]   27 \[7.3\]                86 \[3.5\]         0.0018             
  Number of patients with disease \[%\]                                                                                                         
                                                                                Ischemic heart disease    137 \[36.9\]       524 \[21.6\]       \<0.0001
                                                                                Diabetes                  163 \[43.9\]       734 \[30.3\]       \<0.0001
                                                                                Cerebrovascular disease   77 \[20.8\]        220 \[9.1\]        \<0.0001
                                                                                Hypertension              193 \[52.0\]       1128 \[46.5\]      0.0481

Predictive factors associated with bleeding after administration of anticoagulants {#sec013}
----------------------------------------------------------------------------------

In order to determine the factors associated with bleeding, baseline factors such as background, the number of co-administered anticoagulant drugs, anticoagulants related to drug-drug interactions, bleeding history, and the interaction term for the number of co-administered drugs × age were analyzed between with and without bleeding patient groups after stratification without and with a history of cerebrovascular diseases as the first order analysis; we found a difference in base-conditions in AF patients using multiple logistic regression analysis ([S1 Table](#pone.0238233.s001){ref-type="supplementary-material"}). In the model, female gender, aging for 1 year, number of co-administered drugs, and a history of bleeding were predictive factors for bleeding in the no-cerebrovascular disease group. In the cerebrovascular disease group, the number of co-administered drugs for one co-administered drug, started from warfarin and history of bleeding were predictive factors ([S1 Table](#pone.0238233.s001){ref-type="supplementary-material"}). In both groups, the interaction term for "number of co-administered drugs × age" was observed significantly (p = 0.0208 and 0.0121, respectively).

Based on data shown in first order analysis, we stratified with and without cerebrovascular diseases and age for as young if \<60 years and elderly if aged ≥60 and ≤74 years built in significant predictors for sex, the number of co-administered drugs, anticoagulant agent and past history of bleeding in the first order analysis ([Table 2](#pone.0238233.t002){ref-type="table"}). In the elderly group, the predictive factor for bleeding was a past history of bleeding (without and with cerebrovascular disease: 7.20 \[3.40--15.25\], p\<0.0001 and 11.64 \[4.09--33.13\], p\<0.0001). However, the number of co-administered drugs with DOAC or warfarin were not observed to be a predictive factor for bleeding in our study patients ([Table 2](#pone.0238233.t002){ref-type="table"}). In contrast, in the young group, the number of co-administered drugs was found to be a predictive factor (without and with cerebrovascular disease: 1.09 \[1.03--1.16\], p = 0.0054 and 1.20 \[1.05--1.36\], p = 0.0059). In addition, starting anticoagulation with warfarin (without and with cerebrovascular disease: 1.55 \[1.06--2.27\], p = 0.0042 and 2.98 \[1.16--7.66\], p = 0.0234) and past history of bleeding (without and with cerebrovascular disease: 28.83 \[12.45--66.76\], p\<0.0001 and 6.43 \[4.31--19.78\], p = 0.0006) were also to be significant factors for bleeding ([Table 2](#pone.0238233.t002){ref-type="table"}).

10.1371/journal.pone.0238233.t002

###### Adjusted odds ratio for co-factors associated with bleeding after administration of anti-coagulants using multiple logistic regression analysis stratified based on presence or absence of cerebrovascular disease and age.

![](pone.0238233.t002){#pone.0238233.t002g}

                                                                                            Without cerebrovascular disease (n = 2499)   With cerebrovascular disease (n = 297)                                                                                        
  --------------- --------------------------------------------------------------- --------- -------------------------------------------- ---------------------------------------- ------------------- -------- ------------- --------------------- ------------------- --------
  Age ≥ 60, ≤74                                                                                                                                                                                                                                                        
                  Sex, number                                                     Male      113                                          661                                      Reference                    28            91                    Reference           
                                                                                  Female    41                                           152                                      1.51 (1.01--2.28)   0.0472   13            17                    2.15 (0.84--5.48)   0.1102
                  Number of co-administered drugs, median with range, (+1 drug)             4 (1--16)                                    4 (1--16)                                1.05 (0.99--1.12)   0.0872   6 (1--14)     5.5 (2--15)           1.10 (0.96--1.27)   0.1745
                  Anticoagulant agent, number                                     DOAC      96                                           531                                      Reference                    22            73                    Reference           
                  Warfarin                                                        58        282                                          1.06 (0.73--1.53)                        0.775               19       35            1.99 (0.86--4.60)     0.1059              
                  Past history of bleeding, number                                Without   137                                          800                                      Reference                    24            101                   Reference           
                  With                                                            17        13                                           7.20 (3.40--15.25)                       \<0.0001            17       7             11.64 (4.09--33.13)   \<0.0001            
  Age \< 60                                                                                                                                                                                                                                                            
                  Sex, number                                                     Male      109                                          1240                                     Reference                    31            101                   Reference           
                                                                                  Female    31                                           152                                      2.00 (1.25--3.22)   0.0042   5             11                    1.44 (0.41--5.09)   0.5745
                  Number of co-administered drugs, median with range, (+1 drug)             4.5 (1--18)                                  3 (1--18)                                1.09 (1.03--1.16)   0.0054   7.5 (2--15)   5 (1--15)             1.20 (1.05--1.36)   0.0059
                  Anticoagulant agent, number                                     DOAC      72                                           910                                      Reference                    11            65                    Reference           
                  Warfarin                                                        68        482                                          1.55 (1.06--2.27)                        0.0042              25       47            2.98 (1.16--7.66)     0.0234              
                  Past history of bleeding, number                                Without   115                                          1384                                     Reference                    24            100                   Reference           
                  With                                                            25        8                                            28.83 (12.45--66.76)                     \<0.0001            12       12            6.43 (4.31--19.78)    0.0006              

Discussion {#sec014}
==========

We identified the predictive factors for bleeding after starting anticoagulants in AF patients among young and elderly both in the presence and absence of cerebrovascular disease. In the elderly, only the history of bleeding was a risk factor but in the young, polypharmacy, starting with warfarin, and a history of bleeding were the observed potential predictive factors for bleeding. Anti-coagulant therapy plays an important role in AF patients; the identification of predictive factors associated with bleeding events based on the baseline parameters in AF patients is important for the selection of appropriate anti-coagulants in the real-world clinical settings.

Polypharmacy was observed in 64% of patients in the ROCKT AF study (over five concomitant drugs), 76.5% in the ARISTOLE study (over six concomitant drugs), and 76.9% (over five concomitant drugs) using pharmacy chain dispensing data in Japan \[[@pone.0238233.ref001], [@pone.0238233.ref002], [@pone.0238233.ref009]\]. In the present study, 29.1% (over six concomitant drugs) were identified as being administered polypharmacy using claim data ([Fig 1](#pone.0238233.g001){ref-type="fig"}). In our study, we used JMDC claim data based on "social insurance" because of the absence of considerable socioeconomic differences as compared to those of other insurance members in Japan. In addition, our subjects, included those aged ≤ 74 years and working in large scale companies, and their family members. The prevalence for AF is high in elderly patients. Therefore, the difference in the prevalence of polypharmacy occurred naturally between the previously mentioned large-scale clinical trials and our study population. Our data demonstrate the reliability of prediction in the under-75 working age population with AF.

On stratified detailed analysis, increasing the number of drugs accompanies an increased bleeding risk in young patients with and without history of cerebrovascular diseases (odds ratio: 1.20 and 1.09 for +1 co-administered drugs, respectively p \< 0.01) ([Table 2](#pone.0238233.t002){ref-type="table"}); this is similar to findings of previous reports \[[@pone.0238233.ref001], [@pone.0238233.ref002]\]. In contrast, although elderly had higher risk for bleeding as compared to young patients (with and without cerebrovascular diseases: 27.5%/year and 15.9%/year vs. 24.3%/year and 9.1%/year), did not observed increasing the number of drugs accompanies an increased bleeding risk. The possible reasons for this are as follows: 1) elderly patients have poor physical condition, irrespective of the number of drugs used concomitantly and 2) Japanese have a higher bleeding risk than Caucasians, as reported in large-scale phase 3 studies \[[@pone.0238233.ref010]\].

The advantage of our study was that we identified bleeding risk factors using baseline characteristics of AF patients. Physicians and pharmacists should consider initial bleeding symptoms and counsel patients regarding anti-coagulants accordingly.

We did not assess anti-coagulant medication adherence. Medication adherence is higher in Japan than in other countries \[[@pone.0238233.ref011], [@pone.0238233.ref012]\]. In Japan, low adherence to warfarin was found in approximately 15% \[[@pone.0238233.ref009], [@pone.0238233.ref013]\]. This could partially explain the proportion of bleeding in our study. In the statistical model, LOF was over 0.2 in the model without or with cerebrovascular diseases ([S1 Table](#pone.0238233.s001){ref-type="supplementary-material"}); however, LOF in the model stratified with cerebrovascular diseases and age were under 0.2 ([Table 2](#pone.0238233.t002){ref-type="table"}). These suggests that the prediction may not have enough in the analysis in [Table 2](#pone.0238233.t002){ref-type="table"}.

Conclusion {#sec015}
==========

We identified predictive factors associated with bleeding as life-threatening adverse events in patients treated with anti-coagulants. Elderly and younger patients with AF taking several medications should be monitored for initial bleeding events.

Supporting information {#sec016}
======================

###### Adjusted odds ratio for co-factors associated with bleeding after administration of anti-coagulants using multiple logistic regression analysis stratified based on presence or absence of cerebrovascular disease.

(DOCX)
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Click here for additional data file.
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The authors reported 1) the frequency of polypharmacy in AF patients treated with anti-coagulants; and 2) predictive factors associated with bleeding after starting anti-coagulant treatment using a large claim data in Japan. I think it is an interesting result, but this manuscript does not provide enough data to reach the conclusion. The following issues should be revised:

\#Major issues

The authors described as "The interaction term showed that, in young patients, the risk for bleeding was greater as the number of co-administered drugs increased. By contrast, in elderly patients, the risk for bleeding did not increase with increasing number of co-administered drugs (Table 2)" (p.12, L.178-181）. This result is an important finding in this manuscript, but not enough data has been provided to support it. The supporting data should be presented in a table or figure.

\#Minor issues

In table 2, odds ratio of "number of co-administration drugs\*Age" should be described.

\#Other comments

Is the description of "Direct vitamin K inhibitors (DOAC)"（ｐ.4, L.46）correct ?

Is the symbol in "p\>0.0001" (p.9, L.146) correct ?

Is the number of "2800" (p.11, L.127) correct ?

References No.8 and No.12 are the same, and their descriptions are duplicated.

Reviewer \#3: I read the paper of "Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database" interestingly. I was particularly interested in discussing the relationship between age and the number of co-administered drugs as predictors of bleeding. I recognized that it was a very useful paper in terms of polypharmacy and medical safety.

Please consider the following points.

Please correct \"Shu-toh Kana\" to \"Kana Shu-toh\" in the author part.

How old should elderly patients be considered in this paper? I think it is better to show a specific

age in the discussion.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0238233.r002

Author response to Decision Letter 0

3 Jun 2020

To Reviewer 1

1\. The authors concluded that the interaction term for "number of co-administered drugs \* age" was identified as a predictive factor for bleeding, the evaluation of which was conducted with logistic regression. The logistic regression model adopted for patients without cerebrovascular disease includes several variables such as age and number of co-administered drugs, along with the interaction term. The p-value of the interaction term (p=0.0208) does represent that the interaction is significant, which indicates that the effect of number of co-administration drugs on bleeding is different at different values of age, but does not represent that the interaction term is a significant predictive factor. The same criticism is applicable for the model for patients with cerebrovascular disease. (The above are based on my recognition. Further review by statistician might be preferable.). Although the authors conducted detailed analysis to show that the bleeding risk increased with the increase of concomitant drug administration in younger patients, but did not in elderly patients, the data were not shown. Because these results are declared in the ABSTRACT, the data are so important that they should be presented. The data are also important to validate the interaction term and the model itself eventually.

We appreciate your pertinent observations and suggestions. A co-author, Dr. Koinuma is a statistician, and he analysed our data. According to the suggestion, we added the analysis in table 3 and added the description (line 33-39, 138-141, 216-229, 244-250).

In general, if interactions are found in categorical variables (eg. Sex), stratified analysis is conducted. In our study, interactions occurred between the variables used, namely, age (continuous variable) and the number of co-administered drugs (continuous variable). Therefore, we presented the results descriptively, as continuous variables usually need to be analyzed as continuous variables.

However, Kokkinos P et al. (Lancet 2013; 381: 394-99) reported that on changing continuous variables to categorical variables (MET: metabolic equivalents), they found interactions. In accordance with their analysis, we also changed the continuous variables to categorical variables (age cut off value: 60) (Table 3). The age of 60 years was selected based on the time for drastic changes in the working environment such as retirement, position retirement, or employment status (Table 3). In order to avoid over fitting, we added 4 factors (sex, the number of co-administration drugs, anticoagulant agent, and past history of bleeding) to our model in table 3.

2\. Adequate explanation for the validity of the logistic regression models, especially for the reason for the selection of the variables, is needed, as the authors selected these variables amongst plenty of candidate variables in large claims database.

As suggested, we evaluated the model validity using lack of fitness. In the basic model (Table 2), the fit was adequate. On stratified analysis (Table 3), the value did not fit. We have mentioned this in the manuscript at the method and limitation area (line 143-144, 287-291).

As suggested, the reasons for selecting the included variables have also been mentioned in the manuscript (line 127-132).

3\. The entry criteria, referred in Results section, is not specified elsewhere.

We changed the term "entry criteria" to "case identification flow" to improve clarity (line 159).

3\. Improvements to the English language within the manuscript is desired.

E.g.;

L.27

\... after stratification without and with cerebrovascular diseases\...

L.145

With bleeding patients, prescription pattern for anticoagulants were high for warfarin, but lower for DOACs.

L.182 Table 2.

Adjusted odds ratio for co-factors associates bleeding after administration of anti-coagulants using multiple logistic regression analysis stratified with and without cerebrovascular disease.

cerebovascular -\> cerebrovascular

And so on.

As suggested, we have revised throughout the manuscript, and had it re-edited by a professional English language editing service (Editage). Revised point was wrote in red in the manuscript.

To Reviewer 2

\#Major issues

The authors described as "The interaction term showed that, in young patients, the risk for bleeding was greater as the number of co-administered drugs increased. By contrast, in elderly patients, the risk for bleeding did not increase with increasing number of co-administered drugs (Table 2)" (p.12, L.178-181）. This result is an important finding in this manuscript, but not enough data has been provided to support it. The supporting data should be presented in a table or figure.

We appreciate your pertinent observations and suggestion, and have revised the manuscript accordingly; the stratification in the elderly and young has been included as the second stratified analysis in Table 3 and added the description (line: 33-39, 138-141, 216-229, 244-250).

In general, if interactions are found in categorical variables (eg. Sex), stratified analysis is conducted. In our study, interactions occurred between the variables used, namely, age (continuous variable) and the number of co-administered drugs (continuous variable). Therefore, we presented the results descriptively, as continuous variables usually need to be analyzed as continuous variables.

However, Kokkinos P et al. (Lancet 2013; 381: 394-99) reported that on changing continuous variables to categorical variables (MET: metabolic equivalents), they found interactions. In accordance with their analysis, we also changed the continuous variables to categorical variables (age cut off value: 60) (Table 3). The age of 60 years was selected based on the timing for drastic changes in the working environment such as retirement, position retirement, or employment status (Table 3). In order to avoid over fitting, we added 4 factors (sex, the number of co-administration drugs, anticoagulant agent, and past history of bleeding) to our model in table 3.

\#Minor issues

In table 2, odds ratio of "number of co-administration drugs\*Age" should be described.

The odds ratio for the interaction terms could not be calculated as the changes in the continuous variable \* continuous variable values were complex.

As suggested, we added the details of the second stratified analysis for age in the young and elderly to table 3. The odds ratio for the number of co-administered drugs in the elderly (age ≥ 60, ≤74) was 1.05 \[0.99 -- 1.12\], N.S. in the group without cerebrovascular disease and 1.10 \[0.96 -- 1.27\], N.S. in the group with cerebrovascular disease. In contrast, the values in the young were 1.09 \[1.03 -- 1.16\], p=0.0054 in the group without cerebrovascular disease and 1.20 \[1.05 -- 1.36\], p=0.0059 in the group with cerebrovascular disease (Table 3). We add the description (line 33-39, 138-141, 216-229, 244-250).

\#Other comments

Is the description of "Direct vitamin K inhibitors (DOAC)"（ｐ.4, L.50）correct ?

As suggested, we have revised this to "Direct Oral Anti-Coagulant" (line 50).

Is the symbol in "p\>0.0001" (p.9, L.146) correct ?

We apologize for the error and have revised this from "\>" to "\<" (line 161).

Is the number of "2800" (p.11, L.127) correct ?

We apologize for the error and have revised this from "2800" to "2796" (line 191).

References No.8 and No.12 are the same, and their descriptions are duplicated.

We apologize for the error and have removed ref. 12 and add ref. 8; the reference numbers have also been changed throughout the manuscript.

To Reviewer 3

Reviewer \#3: I read the paper of "Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database" interestingly. I was particularly interested in discussing the relationship between age and the number of co-administered drugs as predictors of bleeding. I recognized that it was a very useful paper in terms of polypharmacy and medical safety.

Please consider the following points.

Please correct \"Shu-toh Kana\" to \"Kana Shu-toh\" in the author part.

We apologize for the error, and have changed \"Shu-toh Kana\" to \"Kana Shu-toh\" (line 5).

How old should elderly patients be considered in this paper? I think it is better to show a specific age in the discussion.

As suggested, we defined elderly individuals as those aged ≥ 60. We have added the details of the analysis for stratification in the young and elderly to table 3, and have added the results of the second stratified analysis for age (in the young and elderly) to table 3. The odds ratio for the number of co-administered drugs in the elderly (age ≥ 60, ≤74) was 1.05 \[0.99 -- 1.12\], N.S. in the group without cerebrovascular disease and 1.10 \[0.96 -- 1.27\], N.S. in the group with cerebrovascular disease. In contrast, the values in the young were 1.09 \[1.03 -- 1.16\], p=0.0054 in the group without cerebrovascular disease and 1.20 \[1.05-- 1.36\], p=0.0059 in the group with cerebrovascular disease (table 3). And we added the description (line 33-39, 138-141, 216-229, 244-250).

###### 

Submitted filename: Revise_letter_20200403KM.docx

###### 

Click here for additional data file.
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PONE-D-20-00210R1

Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database

PLOS ONE

Dear Dr. Momo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your paper was reviewed by the previous three reviewers. Although your manuscript has been improved, there are still some issues regarding data presentation. Please read the comments by Reviewer 1 carefully, and address the issues accordingly.

Please submit your revised manuscript by Aug 29 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Tomohiko Ai, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: There are still some concerns left, although the authors revised the manuscript almost properly. The concerns are as follows, especially \#1-2.

\#1-1

The authors added Table 3 and related description according to stratified analysis by the age of 60 years. The revision is to be appropriate, as these results are quite important to support their opinion.

However, this revision generated another concern; Is Table 2 necessary? The authors conducted stratified analysis because interactions are found. Therefore, the predictive factors should be discussed based on the stratified analysis, as authors have done so.

\#1-2

No explanation is provided about the predictive factors that I have mentioned. i.e. Is the sentence in ABSTRACT, "Multiple logistic regression analysis revealed the following cerebrovascular disease associated predictors of bleeding in both groups: \...3) interaction term for "number of co-administrered drugs × age"" correct? I don't think the expression correct. Is regarding an interaction term as a predictor accurate?

\#2

Explanations for the validity of their regression models and the reasons for selecting variables are thought to be properly added.

\#3

The term "case identification flow" is to be appropriate.

Reviewer \#2: (No Response)

Reviewer \#3: I read the paper of "Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database" interestingly. This study aims to assess the polypharmacy of AF patients treated with anticoagulants and use large claims data to identify predictors associated with bleeding after initiation of anticoagulant treatment However, this is an important and meaningful study for medical safety.

It will be clear what the reviewers have pointed out, and readers of the PLOS ONE Journal will be interested.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0238233.r004

Author response to Decision Letter 1

23 Jul 2020

Responses to the Reviewer's comments (PONE-D-20-00210R1)

We would like to express our gratitude to the reviewers for their insightful comments on our paper. We feel that these comments have helped us to improve the manuscript substantially. Our point-by-point responses to the reviewer's comments can be found below:

Responses to Reviewer:

Comment \#1-1

The authors added Table 3 and related description according to stratified analysis by the age of 60 years. The revision is to be appropriate, as these results are quite important to support their opinion.

However, this revision generated another concern; Is Table 2 necessary? The authors conducted stratified analysis because interactions are found. Therefore, the predictive factors should be discussed based on the stratified analysis, as authors have done so.

Response:

We appreciate your comment on this point. We removed table 3 and changed it to suppl

1\. According to removing table 3, we revised abstract (p2, l34-50), Method (p7, l 147-

p8, l 149), Result (p12, l 212-232) and Discussion (p18, l265-268, p19, l286-p20, l308, p19, l319-321).

Comment \#1-2

No explanation is provided about the predictive factors that I have mentioned. i.e. Is the sentence in ABSTRACT, "Multiple logistic regression analysis revealed the following cerebrovascular disease associated predictors of bleeding in both groups: \...3) interaction term for "number of co-administrered drugs × age"" correct? I don't think the expression correct. Is regarding an interaction term as a predictor accurate?

Response:

We appreciate your comment on this point. According to the suggestion for comment

\#1-1, we removed table 3 and mentioned for only the stratified analysis (young and

elderly) data in revised manuscript. We showed the predictive factor as \"history of

bleeding\" in young and elderly, and \"polypharmacy\" and \"start from warfarin\" in young

in revised manuscript (p2, l43-44, p12, l227-232).

Comment \#2

Explanations for the validity of their regression models and the reasons for selecting variables are thought to be properly added.

Response:

Thank you for your comment.

Comment \#3

The term "case identification flow" is to be appropriate.

Response:

Thank you for your comment.

###### 

Submitted filename: R2 Responses to the Reviewer 20200716KM.docx

###### 

Click here for additional data file.
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PONE-D-20-00210R2

Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database

PLOS ONE

Dear Dr. Momo,

Thank you for submitting your manuscript to PLOS ONE. Your paper was evaluated by the previous reviewer. Based upon the comment, your manuscript is improved to meet the reviewer\'s academic standard. However, some minor changes are suggested, and I would recommend the authors to submit a final version with edits.

Please submit your revised manuscript by Sep 19 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Tomohiko Ai, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Almost all comments have been addressed properly. However, some sentences are left involving syntax errors.

Abstract

p.2 l.34

Bleeding risk assessment using multiple logistic regression analysis, the odds ratio for the number of co-administered drugs in the elderly (age for ≥60, ≤74) was not significant in those without and with cerebrovascular diseases \...

-\>

In bleeding risk assessment using multiple logistic regression analysis, ...

Or

Bleeding risk assessment using multiple logistic regression analysis revealed that the odds ratio...

Results

p.12 l.227

Data shown in first order analysis, we stratified...

-\>

Based on data shown in first order analysis, we stratified...

Discussion

p.19 l.267

We identified the predictive factors for bleeding after starting anticoagulants in AF patients among young and elderly and presence and absence of cerebrovascular disease, only the history of bleeding was a risk factor in the elderly, but in the young, polypharmacy, starting with warfarin, and a history of bleeding were the observed potential predictive factors for bleeding.

-\>

We identified the predictive factors for bleeding after starting anticoagulants in AF patients among young and elderly both in the presence and absence of cerebrovascular disease. In the elderly, only the history of bleeding was a risk factor but in the young, polypharmacy, starting with warfarin, and a history of bleeding were the observed potential predictive factors for bleeding.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 2

10 Aug 2020

Responses to the Reviewer's comments (PONE-D-20-00210R1)

We would like to express our gratitude to the reviewers for their insightful comments on our paper. We feel that these comments have helped us to improve the manuscript substantially. Our point-by-point responses to the reviewer's comments can be found below:

Responses to Reviewer:

Thank you for editing English expression. We revised according to the suggestion.

Comment \#1-1

Abstract

p.2 l.34

Bleeding risk assessment using multiple logistic regression analysis, the odds ratio for the number of co-administered drugs in the elderly (age for ≥60, ≤74) was not significant in those without and with cerebrovascular diseases \...

-\>

In bleeding risk assessment using multiple logistic regression analysis, ...

Or

Bleeding risk assessment using multiple logistic regression analysis revealed that the odds ratio...

Response:

According to the suggestion, we revised to "....multiple logistic regression analysis revealed that the odds ratio...."

Comment \#1-2

Results

p.12 l.227

Data shown in first order analysis, we stratified...

-\>

Based on data shown in first order analysis, we stratified...

Response:

According to the suggestion, we revised to "Based on data ...."

Comment \#1-3

Discussion

p.19 l.267

We identified the predictive factors for bleeding after starting anticoagulants in AF patients among young and elderly and presence and absence of cerebrovascular disease, only the history of bleeding was a risk factor in the elderly, but in the young, polypharmacy, starting with warfarin, and a history of bleeding were the observed potential predictive factors for bleeding.

-\>
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